NB-4746 by Nura Bio for Amyotrophic Lateral Sclerosis: Likelihood of Approval

NB-4746 is under clinical development by Nura Bio and currently in Phase I for Amyotrophic Lateral Sclerosis.

Developing a synthetic pathology framework: A step towards replacing animal testing

Researchers establish AnimalGAN as a reliable alternative for generating synthetic pathology data.

November 10, 2023

AvaSure Acquires Ouva’s Smart Room Solutions to Enhance AI-Powered Virtual Care Platform

What You Should Know: – AvaSure, a provider of acute virtual care, announced today the acquisition of Ouva’s smart room solutions. This strategic move aims

July 29, 2024

Organigram Sells Units to Raise C$25 MIllion

Organigram Announces Pricing of Overnight Marketed Public Offering TORONTO–(BUSINESS WIRE), March 27, 2024–Organigram Holdings Inc. (“Organigram” or the “Company”) (TSX: OGI; NASDAQ: OGI), announces today

March 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.